RANI Rani Therapeutics Holdings,...

Nasdaq ranitherapeutics.com


$ 0.48 $ 0.02 (3.39 %)    

Tuesday, 14-Oct-2025 15:36:21 EDT
QQQ $ 598.05 $ -4.01 (-0.67 %)
DIA $ 462.99 $ 2.03 (0.44 %)
SPY $ 662.22 $ -0.81 (-0.12 %)
TLT $ 90.65 $ 0.29 (0.32 %)
GLD $ 383.08 $ 2.70 (0.71 %)
$ 0.4844
$ 0.46
$ 0.46 x 666
$ 0.49 x 80
$ 0.46 - $ 0.49
$ 0.39 - $ 3.75
462,416
na
34.81M
$ 0.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-16-2021 09-30-2021 10-Q
17 09-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 rani-therapeutics-holdings-files-for-mixed-shelf-offering-of-up-to-200m

-SEC Filing

 rani-therapeutics-hldgs-q2-eps-018-beats-024-estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate ...

 rani-therapeutics-unveils-data-on-robotic-pill-that-matches-injections-in-canine-study-at-endo-2025

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutic...

 rani-therapeutics-holdings-announces-nasdaq-noncompliance-notice

-SEC Filing

 watching-rani-therapeutics-zacks-small-cap-research-gives-stock-12-price-valuation

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05192025_RANI_Vandermosten.pdf

 oppenheimer-maintains-outperform-on-rani-therapeutics-hldgs-lowers-price-target-to-4

Oppenheimer analyst Andreas Argyrides maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform and lowers the price...

 rani-therapeutics-hldgs-q1-eps-022-misses-021-estimate-sales-17200k

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION